These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1096 related items for PubMed ID: 29226369

  • 1. Safety of biologics in psoriasis.
    Kamata M, Tada Y.
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [Abstract] [Full Text] [Related]

  • 2. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [Abstract] [Full Text] [Related]

  • 3. Biologics for Psoriasis.
    Wride AM, Chen GF, Spaulding SL, Tkachenko E, Cohen JM.
    Dermatol Clin; 2024 Jul; 42(3):339-355. PubMed ID: 38796266
    [Abstract] [Full Text] [Related]

  • 4. Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.
    Molinelli E, Campanati A, Brisigotti V, Offidani A.
    Curr Pharm Biotechnol; 2017 Jul; 18(12):964-978. PubMed ID: 29299984
    [Abstract] [Full Text] [Related]

  • 5. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
    Dong J, Goldenberg G.
    Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
    [Abstract] [Full Text] [Related]

  • 6. Japanese guidance for use of biologics for psoriasis (the 2019 version).
    Saeki H, Terui T, Morita A, Sano S, Imafuku S, Asahina A, Komine M, Etoh T, Igarashi A, Torii H, Abe M, Nakagawa H, Watanabe A, Yotsuyanagi H, Ohtsuki M, Biologics Review Committee of the Japanese Dermatological Association for Psoriasis: Chair: Mamitaro Ohtsuki.
    J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
    [Abstract] [Full Text] [Related]

  • 7. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
    Hendrix N, Ollendorf DA, Chapman RH, Loos A, Liu S, Kumar V, Linder JA, Pearson SD, Veenstra DL.
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1210-1217. PubMed ID: 30479197
    [Abstract] [Full Text] [Related]

  • 8. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
    Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, Gisondi P, Daudén E, Conrad C, Mendes-Bastos P, Ferreira P, Leite L, Lu JD, Valerio J, Bruni M, Messina F, Nidegger A, Llamas-Velasco M, Del Alcazar E, Mufti A, White K, Caldarola G, Teixeira L, Romanelli P, Desai K, Gkalpakiotis S, Romanelli M, Yeung J, Nogueira M, Chiricozzi A.
    Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
    [Abstract] [Full Text] [Related]

  • 9. Adverse Reactions to Biologics in Psoriasis.
    Lockwood SJ, Prens LM, Kimball AB.
    Curr Probl Dermatol; 2018 Jul; 53():1-14. PubMed ID: 29131033
    [Abstract] [Full Text] [Related]

  • 10. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.
    D'Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M, Galluzzo M.
    Expert Opin Drug Saf; 2019 Nov; 18(11):1031-1041. PubMed ID: 31479282
    [Abstract] [Full Text] [Related]

  • 11. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
    Tausend W, Downing C, Tyring S.
    J Cutan Med Surg; 2014 Nov; 18(3):156-69. PubMed ID: 24800703
    [Abstract] [Full Text] [Related]

  • 12. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
    Leonardi CL.
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S74-7. PubMed ID: 27551698
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
    Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, Shi Y.
    Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
    [Abstract] [Full Text] [Related]

  • 14. Biologics and Psoriasis: The Beat Goes On.
    Kim HJ, Lebwohl MG.
    Dermatol Clin; 2019 Jan; 37(1):29-36. PubMed ID: 30466686
    [Abstract] [Full Text] [Related]

  • 15. New and emerging therapies in psoriasis.
    Leonardi CL, Gordon KB.
    Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S37-41. PubMed ID: 24979544
    [Abstract] [Full Text] [Related]

  • 16. Secukinumab for treating plaque psoriasis.
    Rothstein B, Gottlieb A.
    Expert Opin Biol Ther; 2016 Mar; 16(1):119-28. PubMed ID: 26577956
    [Abstract] [Full Text] [Related]

  • 17. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C, Sekhon S, Yan D, Afifi L, Nakamura M, Bhutani T.
    Hum Vaccin Immunother; 2017 Oct 03; 13(10):2247-2259. PubMed ID: 28825875
    [Abstract] [Full Text] [Related]

  • 18. Biologics in the treatment of pustular psoriasis.
    Wang WM, Jin HZ.
    Expert Opin Drug Saf; 2020 Aug 03; 19(8):969-980. PubMed ID: 32615817
    [Abstract] [Full Text] [Related]

  • 19. Anti-IL-17 phase II data for psoriasis: A review.
    Brown G, Malakouti M, Wang E, Koo JY, Levin E.
    J Dermatolog Treat; 2015 Feb 03; 26(1):32-6. PubMed ID: 24552447
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
    Gan EY, Chong WS, Tey HL.
    BioDrugs; 2013 Aug 03; 27(4):359-73. PubMed ID: 23580094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.